Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical

GSK/XenoPort Prep RLS Candidate For Phase III In Neuropathic Pain

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Firms plan to initiate pivotal trials of XP13512 in neuropathic pain this year after releasing positive Phase III data for restless legs syndrome.

You may also be interested in...



GSK/SkyePharma’s Requip XL Has Mid-December Action Date

Extended-release ropinirole uses Skye’s proprietary GeoMatrix technology to provide steady levels over 24 hours.

GSK Extends RLS Franchise With Gabapentin Prodrug Through XenoPort Deal

XP13512 is in Phase III development for restless legs syndrome and Phase II for neuropathic pain.

Sanofi Steps Up To Lend A Hand Producing Pfizer/BioNTech's COVID-19 Vaccine In Europe

Sanofi will fill and package 100 million doses of a rival vaccine for the European market in 2021 in a sign of how the industry is working to meet an unprecedented demand for COVID-19 vaccines.

Table

View full table

Topics

Tags:
BioPharmaceutical
UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By